These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 35714304)

  • 1. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease.
    Nyffenegger N; Zennadi R; Kalleda N; Flace A; Ingoglia G; Buzzi RM; Doucerain C; Buehler PW; Schaer DJ; Dürrenberger F; Manolova V
    Blood; 2022 Aug; 140(7):769-781. PubMed ID: 35714304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vamifeport: Monography of the First Oral Ferroportin Inhibitor.
    Pilo F; Angelucci E
    J Clin Med; 2024 Sep; 13(18):. PubMed ID: 39337010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
    Demers M; Sturtevant S; Guertin KR; Gupta D; Desai K; Vieira BF; Li W; Hicks A; Ismail A; Gonçalves BP; Di Caprio G; Schonbrun E; Hansen S; Musayev FN; Safo MK; Wood DK; Higgins JM; Light DR
    Blood Adv; 2021 Mar; 5(5):1388-1402. PubMed ID: 33661300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
    Nader E; Romana M; Connes P
    Front Immunol; 2020; 11():454. PubMed ID: 32231672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
    Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD
    Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired hemoglobin clearance by sinusoidal endothelium promotes vaso-occlusion and liver injury in sickle cell disease.
    Kaminski TW; Katoch O; Li Z; Hanway CB; Dubey RK; Alagbe A; Brzoska T; Zhang H; Sundd P; Kato GJ; Novelli EM; Pradhan-Sundd T
    Haematologica; 2024 May; 109(5):1535-1550. PubMed ID: 37941440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiological characterization of the Townes mouse model for sickle cell disease.
    Alvarez-Argote J; Dlugi TA; Sundararajan T; Kleynerman A; Faber ML; McKillop WM; Medin JA
    Transl Res; 2023 Apr; 254():77-91. PubMed ID: 36323381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
    Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
    Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model.
    Dufu K; Alt C; Strutt S; Partridge J; Tang T; Siu V; Liao-Zou H; Rademacher P; Williams AT; Muller CR; Geng X; Pochron MP; Dang AN; Cabrales P; Li Z; Oksenberg D; Cathers BE
    Br J Haematol; 2023 Jul; 202(1):173-183. PubMed ID: 36960712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease.
    Belcher JD; Nguyen J; Chen C; Abdulla F; Conglin R; Ivy ZK; Cummings J; Dudler T; Vercellotti GM
    Transl Res; 2022 Nov; 249():1-12. PubMed ID: 35878790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular pathophysiology of sickle cell disease.
    Connes P; Renoux C; Joly P; Nader E
    Presse Med; 2023 Dec; 52(4):104202. PubMed ID: 37944640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral carbon monoxide therapy in murine sickle cell disease: Beneficial effects on vaso-occlusion, inflammation and anemia.
    Belcher JD; Gomperts E; Nguyen J; Chen C; Abdulla F; Kiser ZM; Gallo D; Levy H; Otterbein LE; Vercellotti GM
    PLoS One; 2018; 13(10):e0205194. PubMed ID: 30308028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes.
    Brittenham GM; Schechter AN; Noguchi CT
    Blood; 1985 Jan; 65(1):183-9. PubMed ID: 3965046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia.
    Abdulmalik O; Darwish NHE; Muralidharan-Chari V; Taleb MA; Mousa SA
    Haematologica; 2022 Feb; 107(2):532-540. PubMed ID: 33567814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.
    Nader E; Conran N; Romana M; Connes P
    Compr Physiol; 2021 Apr; 11(2):1785-1803. PubMed ID: 33792905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD.
    Liu Y; Zhong H; Bao W; Mendelson A; An X; Shi P; Chou ST; Manwani D; Yazdanbakhsh K
    Blood; 2019 Aug; 134(7):579-590. PubMed ID: 31076443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
    Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS
    Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron restriction in sickle cell disease: When less is more.
    Castro OL; De Franceschi L; Ganz T; Kanter J; Kato GJ; Pasricha SR; Rivella S; Wood JC
    Am J Hematol; 2024 Jul; 99(7):1349-1359. PubMed ID: 38400590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities.
    Alramadhani D; Aljahdali AS; Abdulmalik O; Pierce BD; Safo MK
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking HbS Polymerization in SCD.
    Lettre G
    Cell; 2020 Mar; 180(5):819. PubMed ID: 32142671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.